search button

Effects of nuclear factor-κB and ERK signaling transduction pathway inhibitors on human melanoma cell proliferation in vitro

  • Authors:
    • Yi‑Chuan Huang
    • Min Pan
    • Ning Liu
    • Jun‑Gang Xiao
    • Hong‑Quan Chen

  • View Affiliations

  • Published online on: September 3, 2015     https://doi.org/10.3892/ol.2015.3672
  • Pages: 3233-3237
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the effects of blocking nuclear factor (NF)-κB and/or extracellular signal-regulated kinase (ERK) signaling pathways on proliferation and apoptosis of melanoma cells in vitro. A375 Human melanoma cells were treated with U0126 (ERK signaling pathway inhibitor) and BMS-345541 (NF-κB inhibitor), alone or in combination. At 12, 24 and 48 h after treatment, cell viability was assessed using the 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide assay, cell cycle progression and apoptosis were evaluated by flow cytometry, and Bcl‑2 protein content was determined by western blot analysis. BMS‑345541 and U0126 significantly inhibited A375 cell proliferation in a dose‑ and time‑dependent manner (P<0.01). The rate of proliferation inhibition at 24 h was 35.41±1.38% for BMS‑345541 alone, 30.64±2.86% for U0126 alone, and 77.27±2.70% for BMS‑345541 and U0126 in combination. The difference between combination and single treatment was significantly different (P<0.01). The proportion of cells in S phase was 14.20, 18.40 and 22.64% following treatment with BMS‑345541, U0126, and BMS‑345541 and U0126 in combination, respectively; these values were all significantly reduced compared with the untreated control group (P<0.01). The apoptosis rate was 24.98±1.03% in the BMS‑345541 group, 13.96±0.96% in the U0126 group and 38.91±1.46% in the combination group; all significantly increased compared with the control group (P<0.01). Bcl‑2 protein content in A375 cells was significantly increased following treatment with BMS‑345541 and U0126, alone or in combination, when compared with the untreated control group (P<0.01). Therefore, NF-κB and ERK signaling pathway inhibitors may serve as potential therapeutic targets for melanoma.
View Figures
View References

Related Articles

Journal Cover

November-2015
Volume 10 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Huang YC, Pan M, Liu N, Xiao JG and Chen HQ: Effects of nuclear factor-κB and ERK signaling transduction pathway inhibitors on human melanoma cell proliferation in vitro. Oncol Lett 10: 3233-3237, 2015.
APA
Huang, Y., Pan, M., Liu, N., Xiao, J., & Chen, H. (2015). Effects of nuclear factor-κB and ERK signaling transduction pathway inhibitors on human melanoma cell proliferation in vitro. Oncology Letters, 10, 3233-3237. https://doi.org/10.3892/ol.2015.3672
MLA
Huang, Y., Pan, M., Liu, N., Xiao, J., Chen, H."Effects of nuclear factor-κB and ERK signaling transduction pathway inhibitors on human melanoma cell proliferation in vitro". Oncology Letters 10.5 (2015): 3233-3237.
Chicago
Huang, Y., Pan, M., Liu, N., Xiao, J., Chen, H."Effects of nuclear factor-κB and ERK signaling transduction pathway inhibitors on human melanoma cell proliferation in vitro". Oncology Letters 10, no. 5 (2015): 3233-3237. https://doi.org/10.3892/ol.2015.3672